Healthcare
Indivior Pharmaceuticals Inc(INDV)
Live Price
Offline$38.88
+1.51% today
1Y Change
+178.95%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $4.59B
- Revenue Growth
- +4.3%
- EPS Growth
- +11025.8%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Indivior Pharmaceuticals Inc (INDV) is a Healthcare stock with a market cap of $4.59B and listed on NASDAQ. The stock last traded around $38.88 and up 179.0% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +4.3%, EPS growth of +11025.8%, a dividend yield of 0.0%. What stands out right now is revenue +4.3%, EPS +11025.8%, free cash flow -1428.6% with operating margin 29.0% and ROIC 74.5%. Valuation is more restrained than many high-expectation growth names at P/E 18.1 and price/sales 3.6. Stock Foundry combines INDV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.3% vs +7.6% peer median
Operating Margin
Above sector median
+29.0% vs +19.4% peer median
P/E
Below sector median
18.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +4.3% and EPS at +11025.8%, with operating margin around 29.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +5.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.2% | +10.9% | +13.0% |
2026 Feb 26, 2026 | +26.1% | -2.9% | -4.9% | -11.2% |
2025 Oct 30, 2025 | +89.5% | +0.8% | +9.4% | +15.3% |
Benchmark Edge
INDV vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INDV
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INDV Max Drawdown
-21.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INDV and SPY.
Company Overview
Indivior Pharmaceuticals Inc
NASDAQ Global Select
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
- Leadership
- Joseph J. Ciaffoni
- IPO Date
- Dec 29, 2014
- Employees
- 1.0k
- Street Address
- 10710 Midlothian Turnpike
- Mailing
- North Chesterfield, VA, 23235
- Region
- North Chesterfield, VA, US
- Reporting Currency
- USD
- Investor Line
- 804 379 1090
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.1
- EV/EBITDA
- 12.3
- Price/Sales
- 3.6
- Price/Book
- โ
Growth
- Revenue
- +4.3%
- EPS
- +11025.8%
- Free Cash Flow
- -1428.6%
Profitability
- Gross Margin
- 81.4%
- Operating Margin
- 29.0%
- Net Margin
- 19.5%
- ROE
- -142.6%
- ROIC
- 74.5%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.86
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.